Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.
Exogenous cholecystokinin (CCK) induces early satiety when infused into humans. Whether alimentary CCK (CCK-A) receptor blockade stimulates food intake in humans is, however, uncertain. The aim of the present investigation was, therefore, to establish the effect of CCK-A receptor blockade on satiety and eating behavior in healthy volunteers. To further explore the role of endogenous CCK, the effects of the specific CCK-A receptor antagonist loxiglumide (Lox; 22 micromol. kg(-1). h(-1)) on satiety and eating behavior were investigated in healthy men and compared with saline infusions (as placebo) in a series of randomized, double-blind, placebo-controlled, crossover studies. Lox produced a slight (7%), but not significant (P = 0.104), increase in food intake that was accompanied by a modest (10%), but significant (P < 0.004), increase in calorie intake. Fluid ingestion was not affected by Lox. Subjects experienced more hunger and delayed fullness during Lox infusion than during saline infusion (P < 0.05). This study provides further evidence that CCK is an endogenous physiological satiety signal acting through CCK-A receptor-mediated mechanisms. Repeated-dose studies comparing hunger and satiety responses after CCK-A receptor blockade in healthy subjects and patients with eating disorders may help clarify the possible involvement of endogenous CCK in these conditions.
Beglinger
C
C
Department of Research, Division of Gastroenterology, University Hospital, CH-4031 Basel, Switzerland.
Degen
L
L
Matzinger
D
D
D'Amato
M
M
Drewe
J
J
D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004327:Drinking Behavior / Q000187:drug effects / Q000502:physiology; D002149:Energy Intake / Q000187:drug effects*; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D006815:Hunger / Q000187:drug effects / Q000502:physiology*; D008297:Male; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011897:Random Allocation; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D012016:Reference Values; D012527:Satiation / Q000187:drug effects* / Q000502:physiology
D006727:Hormone Antagonists; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; C053737:loxiglumide; D011377:Proglumide